The effects of age and gender on the pharmacokinetics of irbesartan

British Journal of Clinical Pharmacology

Volumn 46, Issue 6, 1998, Pages 611-613

  Vachharajani, Nimish N ^a   Shyu, Wen Chyi ^b   Smith, Robert A ^b   Greene, Douglas S ^b  

^a Departmentof Metabolism and Pliannacokineties   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Age; Gender; Irbesartan; Pharmacokinetics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; IRBESARTAN;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; PRIORITY JOURNAL; URINALYSIS;

ADOLESCENT; ADULT; AGED; AGING; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIPHENYL COMPOUNDS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; SEX CHARACTERISTICS; TETRAZOLES;

EID: 0031751158     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00837.x     Document Type: Article

References (15)

1. Johnston CJ. Angiotcnsin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-1407.
2. Timmermans PB, Wong PC, Chiu AT, et al. Angiotcnsin II receptors and angiotensin II antagonists. Pliannacol Rev 1993; 45: 205-251.
3. Eberhardt RT, Kevak RM, Kang PM, Frishman WH. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy.J Clin Pliannacol 1993; 33: 1023-1038.
4. Cazaubon C, Gougat J, Bousquet F, et al. Pharmacological characterization of SR 47436, a new nonpeptide ATI subtype angiotensin II receptor antagonist. J Pliannacol Exp Tlier 1993; 265: 826-834.
5. Van den Meiracker AH, Admiraal PJ, et al. Hemodynamic and biochemical effects of the AT] receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-29.
6. Marino MR, Langenbacher KM, Raymond RH, Whigan D, Ford NF. Pharmacokinetics (PK) and antihypertensive effects of irbesartan (an All receptor antagonist) in subjects with hypertension. J Hypertens 1996; 14: S348.
7. Marino MR, Langenbacher KM, Ford NF, Uderman HD. Phannacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pliannacol 1998; 38: 246-255.
8. Chang S-Y, Whigan DB, Vachharajani NN, Patel R. A highperformance liquid chromatography assay for quantitation of irbesartan (SR 47436/BMS-l 86295) in human plasma and urine. J Cliromagr B 1997; 702: 149-155.
9. Gibaldi M, Ferner D. Phannacokinetics, 2nd edn, Marcel Dekker, Inc., New York, NY, 1982, pp. 409-417.
10. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of m vivo dissolution time and absorption time. J Pliannacokin Biophann 1980; 8: 509-534.
11. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: Results from the third national health and nutrition examination survey, 1988-91. Hypertension 1995; 25: 305-313.
12. Vachharajani NN, Shyu WC, Chando TJ, Everctt DW, Greene DS, Barbhaiya RH. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in man. J Clin Pliannacol 1998; 38: 702-707.
13. Ritschel WA. Gerentokinetics, Telford Press, Caldwell, NJ, 1988. (
14. Sica DA, Marino MR, Hammett JL, Ferreira I, Ford NF. Phannacokinetics of irbesartan are not altered by renal impairment or hemodialysis. Clin Pliannacol Tlier 1997; 62: 902-909.
15. Pool JL, Guthrie RM, Littlejohn TN, et al Dose-related antihypertensive effects of irbesartan in patients with mild-tomoderate hypertension. Am J Hypertens 1998; 11: 462-470.